Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GOTICK (also known as Tick-Vac) is a recombinant veterinary vaccine developed by LIMOR de Colombia S.A.S. for the control of the cattle tick, *Rhipicephalus (Boophilus) microplus*. Formulated as an oil-based emulsion, the vaccine utilizes recombinant antigens—specifically the Bm86 midgut protein—to stimulate a protective humoral immune response in bovine hosts. When ticks ingest blood from vaccinated cattle, host antibodies target and damage the tick's intestinal wall, leading to impaired nutrient absorption, reduced reproductive capacity, and increased mortality. This immunological approach provides a sustainable alternative or complement to traditional chemical acaricides, helping to manage tick populations and reduce the transmission of tick-borne diseases such as babesiosis and anaplasmosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GOTICK.